Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Soft-Tissue Sarcomas
NCT06308419Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- Feb 2029
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-sirolimus in leiomyosarcoma (LMS) and soft tissue sarcoma (STS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 1 year and Safety and adverse events at 1 year. Started Aug 2024; status: active, not recruiting.
02
Drugs
nab-sirolimus
03
Conditions
leiomyosarcoma (LMS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06308419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308419.